

1 **Serum biomarkers and anti-flavivirus antibodies at presentation as indicators of severe**
2 **dengue**

3

4 **Running Title:** Serum biomarkers of severe dengue

5

6 Cynthia Bernal^{1*} and Sara Ping^{2*}, Alejandra Rojas¹, Oliver Caballero¹, Victoria Stittleburg²,
7 Yvalena de Guillén¹, Patricia Langjahr³, Benjamin A. Pinsky^{4,5}, Marta Von-Horoch⁶, Patricia
8 Luraschi⁶, Sandra Cabral⁶, María Cecilia Sánchez⁷, Aurelia Torres⁷, Fátima Cardozo^{1,7†,#} and
9 Jesse J. Waggoner^{2,8†,#}

10

11 ¹ Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud, San
12 Lorenzo, Paraguay

13 ² Emory University School of Medicine, Division of Infectious Diseases, Atlanta, GA, USA

14 ³ Universidad Nacional de Asunción, Facultad de Ciencias Químicas, San Lorenzo, Paraguay

15 ⁴ Department of Pathology, Stanford University School of Medicine, California, USA

16 ⁵ Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford
17 University School of Medicine, California, USA

18 ⁶ Hospital Central - Instituto de Previsión Social, Departamento de Epidemiología, Asunción,
19 Paraguay

20 ⁷ Hospital Central - Instituto de Previsión Social, Departamento de Laboratorio de Análisis
21 Clínicos, Asunción, Paraguay

22 ⁸ Rollins School of Public Health, Department of Global Health, Atlanta, GA, USA

23 **Abstract**

24 **Background**

25 Dengue is the most common vector-borne viral disease worldwide. Most cases are mild, but some
26 evolve into severe dengue (SD), with high lethality. Therefore, it is important to identify
27 biomarkers of severe disease to improve outcomes and judiciously utilize resources.

28

29 **Methods/Principal Findings**

30 One hundred forty-five confirmed dengue cases (median age, 42; range <1-91 years), enrolled
31 from February 2018 to March 2020, were selected from an ongoing study of suspected arboviral
32 infections in the Asunción metropolitan area. Cases included dengue virus types 1, 2, and 4, and
33 severity was categorized according to the 2009 World Health Organization guidelines. Serologic
34 and biomarker (lipopolysaccharide binding protein and chymase) testing were performed on acute-
35 phase samples by ELISA; additional serologic testing was performed with the multiplex pGOLD
36 assay. Complete blood counts and chemistries were performed at the discretion of the care team.
37 Age, gender, and pre-existing comorbidities were associated with SD vs. dengue with/without
38 warning signs in logistic regression with odds ratios (ORs) of 1.06 (per year; 95% confidence
39 interval, 1.02, 1.10), 0.12 (female; 0.03,0.5), and 9.82 (presence; 1.92, 50.24) respectively. In
40 binary logistic regression, for every unit increase in anti-DENV IgG in the pGOLD assay, odds of
41 SD increased by 2.54 (1.19-5.42). Platelet count, lymphocyte percent, and elevated chymase were
42 associated with SD in a combined logistic regression model with ORs of 0.99 (1,000/ μ L;
43 0.98,0.999), 0.92 (%; 0.86,0.98), and 1.17 (mg/mL; 1.03,1.33) respectively.

44

45 **Conclusions**

46 Multiple, readily available factors were associated with SD in this population. These findings
47 will aid in the early detection of potentially severe dengue cases and inform the development of
48 new prognostics for use in acute-phase and serial samples from dengue cases.

49 **Author Summary**

50 Dengue fever is an acute disease caused by dengue virus and transmitted to humans through the
51 bite of infected *Aedes* mosquitoes. Dengue is the most common vector-borne viral disease
52 worldwide affecting an estimated 50-100 million people and with 10,000 dengue-related deaths
53 each year. Currently, there is no specific treatment, and safe and effective vaccines have not been
54 fully implemented. Most dengue cases present with nonspecific mild symptoms, but some will
55 evolve into severe dengue, which can be fatal. Early detection and subsequent timely treatment
56 have been shown to decrease mortality among severe cases. Therefore, it is very important to
57 identify biomarkers for the early identification of cases at risk for progression to severe disease.
58 In this study we analyze demographic factors, clinical laboratory data, lipopolysaccharide
59 binding protein and chymase to evaluate associations with disease severity. This study was
60 carried out in Paraguay, which is a hyperendemic country for dengue where the disease has been
61 understudied. A number of factors were found to be associated with severe disease in this
62 population, including patient age, male gender, presence of comorbid illnesses, low platelet
63 count, low lymphocyte percentage, and elevated chymase level.

64 **Introduction**

65 Dengue is a common acute febrile illness in tropical and subtropical regions of the world and
66 accounts for upwards of 10% of such illnesses in areas of endemicity [1-3]. Each year, an estimated
67 50-100 million dengue cases and 10,000 dengue-related deaths occur worldwide, resulting from
68 infection with one of the four types of dengue virus (DENV, genus *Flaviviridae*) [1, 3, 4]. Dengue
69 severity ranges dramatically from a mild subclinical illness to dengue fever and clinically severe
70 dengue with plasma leakage, hemorrhage, and/or end-organ dysfunction [1, 3, 5, 6]. Timely
71 diagnosis and the initiation of appropriate supportive care improves clinical outcomes and can
72 lower mortality in clinically severe dengue from 20% to <1% [1, 3, 7, 8]. Although clinically
73 severe cases represent a minority of dengue cases overall, fatal and hospitalized non-fatal cases
74 account for over half of the \$8.9 billion USD annual economic burden of dengue [6, 9]. Therefore,
75 early identification of cases at increased risk for developing clinically severe dengue could both
76 improve clinical outcomes and alleviate the economic burden caused by dengue on resource
77 constrained medical systems [10].

78
79 Clinically severe dengue results from a complex interplay of virus [11-14], host [15-22], and
80 epidemiologic factors [1, 6, 15]. The manifestations of severe dengue also differ based on patient
81 age, with children more commonly developing plasma leakage compared to hemorrhage in adults
82 [6, 23, 24]. Studies have identified associations between the detection and/or concentration of
83 various molecules or gene transcripts and severe dengue [25-30]. One group of biomarkers that
84 has been studied are proteins released during mast cell degranulation: vascular endothelial growth
85 factor (VEGF) and the proteases tryptase and chymase [31-41]. In studies of patients from South
86 and Southeast Asia, chymase was associated with and predictive of the development of clinically

87 severe dengue [31, 32, 34, 35, 38]. Chymase release from mast cells occurs in the presence of
88 DENV and may be increased by pre-existing anti-DENV IgG antibodies or blocked by antibodies
89 against viral non-structural protein 1 (NS1) [33, 42]. Lipopolysaccharide (LPS) and
90 lipopolysaccharide binding protein (LBP) are another set of molecules that have higher levels in
91 dengue cases compared to healthy controls and in clinically severe cases compared to dengue
92 fever, which could indicate their usefulness as a predictor of severity [43-46]. Elevated levels of
93 circulating LPS and LBP result from derangements in gut permeability, potentially leading to
94 bacterial translocation, bacteremia, and worsened outcomes. Finally, numerous clinical laboratory
95 findings have been associated with clinically severe dengue, such as thrombocytopenia,
96 lymphopenia, and evidence of liver or kidney injury [13, 17, 24, 46-48]. These may either define
97 cases as clinically severe with end-organ dysfunction or predict the development of severe dengue
98 through detection of changes over the course of illness [3].

99
100 The objective of the current study was to evaluate biomarkers of dengue severity among
101 participants enrolled in an ongoing study of acute arboviral illness in the metropolitan area of
102 Asunción, Paraguay. Paraguay is hyperendemic for dengue, with sustained viral circulation since
103 1999 and large disease outbreaks occurring every 2-5 years. In 2018, predominant circulation of
104 DENV-1 was recorded [49], and in 2019-2020, this shifted to DENV-4, resulting in the largest
105 outbreak in the country's history [50]. Previous studies from Paraguay have found an increased
106 risk of clinically severe dengue with DENV-2 and secondary infections [51-53]. However, dengue,
107 and in particular biomarkers of severe disease, remains understudied in the country [54, 55].
108 Previously, our group evaluated anti-DENV and anti-ZIKV NS1 IgG levels among dengue cases
109 in 2018 using a multiplex serological assay, the pGOLD assay [56]. Anti-DENV IgG levels in the

110 pGOLD assay correlated with focus reduction neutralization test (FRNT50) titers, and an
111 association was observed between hospitalization and detection of both anti-DENV and anti-ZIKV
112 IgG. However, hospitalization is an inexact measure of clinical dengue severity. Therefore, in the
113 current study, we sought to evaluate this earlier finding and levels of chymase and LBP as
114 indicators of dengue severity among participants categorized according to the 2009 World Health
115 Organization guidelines [3].

116

117

118 **Methods**

119 **Ethics statement**

120 The study protocol was reviewed and approved by the Scientific and Ethics Committee of the
121 Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción (IICS-
122 UNA, IRB00011984), and the Emory University Institutional Review Board (IRB00000569).

123 A written consent was obtained from all the participants, or alternatively an oral consent.

124

125 **Clinical samples**

126 Individuals included in the current study were enrolled in an ongoing parent study of suspected
127 arboviral infections in the Asunción metropolitan area between February 2018 and March 2020.

128 Participants of both genders and all ages were enrolled as outpatients at IICS-UNA in all study
129 years and in the emergency care/inpatient facilities of Hospital Villa Elisa, 2018, and Hospital
130 Central of the Instituto de Previsión Social, 2019-2020. Inclusion criteria for the parent study
131 were an acute illness including two or more of the following symptoms: fever (measured or
132 subjective), red eyes, rash, joint pain involving more than one joint, and/or diffuse muscle pain.

133 Patients with fever and no other localizing signs or symptoms were also included. Day 1 was
134 defined as the first day of symptoms.

135

136 One hundred forty-five participants with acute dengue and up to 7 days of symptoms were
137 selected for the current analysis. Cases were classified according to the 2009 WHO criteria as
138 dengue without warning signs (DWS-), dengue with warning signs (DWS+) and severe dengue
139 (SD) [3]. For categorization as DWS+, it was necessary to have at least one warning sign. For
140 categorization as SD, an individual had to develop at least one criterion for SD during the
141 clinical course. To maximize study power, all SD cases in the parent study were included in this
142 analysis. A mixture of DWS- and DWS+ cases was then selected to achieve a representative
143 distribution of participants based on age, days of symptoms, comorbidities, and gender from
144 across the study period and to maintain an even distribution of these two categories.

145

146 **Laboratory testing**

147 Acute-phase serum or plasma samples were collected at study enrollment and transported to the
148 IICS-UNA laboratory. Samples were tested for DENV NS1 antigen using the Standard Q
149 Dengue Duo rapid immunochromatographic test (SD Biosensor, Suwon, South Korea) according
150 to manufacturer recommendations. Qualitative antibody data acquired using this method was not
151 evaluated in this study, see antibody section below. Primary samples were then aliquoted and
152 stored at -80°C until later use or shipment on dry ice to Emory University for additional testing.
153 For molecular testing, total nucleic acids were extracted from 200 μL of sample on an EMAG
154 instrument and eluted into 50 μL of buffer. Samples were tested for Zika virus, chikungunya
155 virus and DENV by real-time RT-PCR (rRT-PCR) using a validated and published multiplex

156 assay (the ZCD assay) [57], and DENV serotype and viral load were determined with a
157 published DENV multiplex assay [58, 59]. Both rRT-PCRs were performed as previously
158 described [57-59].

159
160 Serologic testing was performed on acute-phase samples using two different methods. First, anti-
161 DENV IgG and IgM were analyzed using commercial ELISA kits [Dengue ELISA IgG (G1018)
162 and Dengue ELISA IgM Capture (M1018), Vircell Microbiologists, Granada, Spain] according to
163 manufacturer recommendations (interpretation: IgM or IgG index >11 positive, 9-11
164 indeterminate, <9 negative). Second, a 5 μ L aliquot of serum from 139 participants with sufficient
165 sample was tested in the pGOLD assay (Nirmidas Biotech, Inc, Palo Alto, CA), which is a
166 multiplex serological assay for IgM and IgG against DENV (DENV-2 whole virus antigen) and
167 ZIKV (NS1 antigen). The pGOLD assay was performed as previously described [56, 60]. In each
168 well of the pGOLD slide, antigens are spotted in triplicate, and average signals are used during
169 analysis. For IgG, the negative control signal was subtracted from the sample signal, and the
170 difference was divided by the average signal of four IgG control spots included in each well. For
171 IgM, a similar calculation was performed using the signal from a known anti-DENV IgM positive
172 control sample included on each run. A positive threshold ratio of 0.1 was established for each
173 isotype, which was ≥ 3 standard deviations above the mean of the negative control.

174
175 Chymase and LBP levels were determined using commercial ELISA kits (G-Biosciences, St.
176 Louis, MO, USA), following the manufacturer's instructions. Complete blood counts and
177 chemistries were performed at the clinical site at the discretion of the care team, and results were
178 included if the sample was obtained within ± 1 day of enrollment.

179

180 **Case definitions**

181 Dengue cases were defined as individuals who met inclusion criteria for the parent study and had
182 1) detectable DENV RNA in the ZCD and/or DENV multiplex rRT-PCR, 2) detection of DENV
183 NS1 by rapid test, or 3) a strong epidemiologic link (one patient, DWS-).

184

185 **Statistical analysis**

186 Basic statistical analyses were performed using Excel software (Microsoft, Redmond, WA).
187 Comparisons between group means and medians were made by the ANOVA, Welch's test, both
188 pooled and non-pooled two sample t-tests, and Kruskal Wallis tests. Comparisons of proportions
189 were made using chi-squared tests or Fisher exact tests (if the expected number in each cell was
190 <5). Graphs were prepared with GraphPad Prism version 9 (GraphPad, San Diego, CA). Crude
191 associations, statistical analysis and modeling were performed using SAS version 9.4. To calculate
192 odds ratios for SD, domain models were developed using demographic (age, gender,
193 comorbidities) and laboratory variables (basic clinical laboratory results, DENV viral load,
194 chymase and LBP). Models were evaluated using binomial logistic regression (DWS-/DWS+ vs.
195 SD). Significance was set at two-sided p-value ≤ 0.05 for all analyses.

196

197

198 **Results**

199 **Demographic and clinical information.** Of 145 participants in this study, 55 were categorized
200 as DWS-, 67 as DWS+, and 23 as SD. Demographic data and DENV diagnostic test results are
201 shown in Table 1 (binary categories) and Table S1 (three categories). Participants were enrolled

202 primarily at Hospital Central of the Instituto de Previsión Social (n=124), followed by Hospital
 203 Villa Elisa (15) and IICS-UNA (6). Results for DWS- and DWS+ were not significantly different
 204 for most analyses performed in this study. As such, results are reported for analyses using the
 205 binary outcome of DWS-/DWS+ vs. SD, except where indicated. Data and analyses for the three
 206 individual categories are provided in the Supplemental Material.

207

208 **Table 1.** Demographic data and DENV diagnostic test results for participants stratified by
 209 dengue severity.

Characteristic ^a	DWS-/DWS+	SD	p-value
	N=122	N=23	
Age, years, mean (st. dev.)	34 (18)	61 (18)	<0.001
Gender, female	81 (66.4)	6 (26.1)	<0.001
Comorbidities, $\geq 1^b$	31 (25.8)	16 (84.2)	<0.001
Days of symptoms, mean (st. dev.)	3.9 (1.9)	4.8 (1.7)	0.033
Year of Collection			0.015
2018	14 (11.5)	4 (17.4)	
2019	42 (34.4)	1 (4.3)	
2020	66 (54.1)	18 (78.3)	
DENV rRT-PCR, positive	110 (90.2)	20 (90.9)	1.00
Serotype			0.45
DENV-1	14 (12.7)	4 (20.0)	
DENV-2	9 (8.2)	0 (0)	
DENV-4	86 (78.2)	16 (80.0)	

Negative	1 (0.9)	0 (0)	
NSI, positive	77 (63.1)	21 (91.3)	0.010

210 Abbreviations: st. dev., standard deviation

211 ^a Presented as n (%) unless stated otherwise

212 ^b Comorbidities: hypertension, 32; diabetes, 14; other, 30. Comorbidity data missing for DWS+
213 (2) and SD (4).

214
215 SD cases were significantly older than non-SD cases and were significantly more likely to be
216 male and have at least one comorbidity (Table 1). In logistic regression of these variables in
217 relation to disease severity, age, gender, and comorbidities remained in the model and were
218 predictors of severity with a strong goodness of fit (C statistic=0.93; Table 2). In addition, SD
219 cases presented for care later in the course of illness than non-severe cases (Table 1), and more
220 SD cases were included 2020, consistent with the large DENV-4 outbreak that occurred in
221 Paraguay that year [61].

222

223 **Table 2.** Binomial logistic regression of participant demographics and disease severity.

Characteristic	<u>SD vs. DWS-/DWS+</u>	
	OR	95% CI
Age, years	1.06	1.02, 1.10
Gender, female	0.12	0.03, 0.50
Comorbidity, presence	9.82	1.92, 50.24

224 Abbreviations: CI, confidence interval; OR, odds ratio

225

226 **DENV testing**

227 One hundred forty-four of 145 dengue cases (99.3%) tested positive by rRT-PCR, NS1 rapid
228 test, or both; and only one case was included based epidemiologic criteria alone. Over 90% of
229 cases tested positive for DENV by rRT-PCR, and this did not differ between severity categories
230 (Table 1 and Table S1). The proportion of DWS-/DWS+ cases with detectable NS1 (77/122,
231 63.1%) was significantly lower than SD cases (21/23, 91.3%; $p=0.010$). DENV-4 was the
232 predominant type, present in 78.5% of the typed samples overall (102/130).

233

234 Acute-phase samples were tested with two serologic tests: the pGOLD assay for anti-DENV and
235 anti-ZIKV IgM and IgG, and a commercial ELISA for anti-DENV IgM and IgG (Table 3 and
236 Table S2). The proportion of individuals with detectable anti-DENV IgM was significantly
237 higher with the pGOLD assay ($p<0.001$, Table S3). Although a smaller proportion of SD cases
238 had detectable anti-DENV IgM compared to DWS-/DWS+ cases by either method, this
239 difference only reached significance for the pGOLD assay. Most participants had detectable anti-
240 DENV IgG by either method: 120/139 (86.3%) in the pGOLD, 128/145 (88.3%) by commercial
241 ELISA. The proportion of individuals with detectable anti-DENV IgG did not differ significantly
242 by severity category (Table 3 and Table S2) or test method ($p=0.07$, Table S3).

243

244 **Table 3.** Serologic test results stratified by disease severity.

Serologic Test	DWS-/DWS ⁺ ^a	SD ^a	p-value
<i>pGOLD</i> ^b			

DENV IgM	71/119 (59.7%)	7/20 (35.0%)	0.040
DENV IgG	102/119 (85.7%)	18/20 (90.0%)	1.00
ZIKV IgM	5/119 (4.2%)	0/20 (0%)	1.00
ZIKV IgG	19/119 (16.0%)	4/20 (20.0%)	0.52
<i>ELISA</i>			
DENV IgM	40/122 (32.8%)	5/23 (21.7%)	0.40
DENV IgG	106/122 (86.9%)	22/23 (95.7%)	1.00

245 ^a Presented as positive/tested (%)

246 ^b pGOLD testing was performed on 139 participants with sufficient serum available

247

248 The pGOLD assay yields a quantitative result that correlates with DENV neutralizing titers [56].

249 In crude binary logistic regression, for every unit increase in anti-DENV IgG, the odds of SD

250 increased by a factor of 2.54 (95% CI, 1.19-5.42). No association was found between

251 quantitative anti-DENV IgM results and disease severity in crude binary logistic regression.

252

253 **Clinical laboratory data**

254 Mean values for most routine laboratory tests, LBP, and chymase differed significantly between


255 DWS-/DWS+ and SD cases (Fig 1, Table S4). Laboratory values were similar between DWS-

256 and DWS+ cases except for platelet count, which demonstrated a stepwise decrease from DWS-

257 to DWS+ to SD, and serum glutamic oxaloacetic transaminase (SGOT) and LBP, which

258 increased across severity categories (Fig S1, Table S5). DENV viral load did not differ by
259 severity category.

260 **Fig 1. A-I)** Clinical laboratory test result distributions by disease severity. **J-L)** Potential markers
261 of disease severity measured in the current study: J) lipopolysaccharide binding protein (LBP),
262 K) chymase, and L) DENV viral load by disease category. Bars on all graphs represent mean and
263 standard deviation. Labels on the graphs indicate the following: ns, not significant, $p > 0.05$; *,
264 $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$; ****, $p \leq 0.0001$.



266
267 Routine laboratory tests were obtained at the discretion of the clinical care team, and as a result,
268 many participants were missing data, particularly for analytes in the metabolic panel: creatinine
269 (n=75 cases with results), bilirubin (76), and SGOT (84). Due to this fact, crude associations
270 with SD were calculated for all variables by binomial regression (Table 4), and variables
271 evaluated in the laboratory domain multivariable logistic regression were limited to lymphocyte
272 percent, platelet count, hematocrit, LBP, and chymase. These analytes displayed crude
273 associations with SD and had a sufficient number of data points to not compromise model
274 strength. In the binary logistic regression model, lymphocyte percent, platelet count, and
275 chymase were found to be associated with SD with a very good model fit (C statistic, 0.95; Table
276 5).

277

278 **Table 4.** Crude associations between laboratory results and dengue severity from binomial
279 logistic regression.

Laboratory Value	DWS-/DWS+ ^a	SD ^a	OR for SD ^b
Bilirubin (mg/dL)	0.49±0.26	2.51±2.11	29.03 (3.74, 225.04)
Blood Creatinine (mg/dL)	0.85±0.22	3.76±2.29	372.71 (4.38, >999)
Chymase (mg/mL)	1.2±5.8	30.0±28.9	1.12 (1.06, 1.18)
Hematocrit (%)	39.4±4.5	35.9±8.2	0.89 (0.82, 0.97)
LBP (1,000 ng/mL)	11,917±5,030	18,766±5,510	1.28 (1.11, 1.40)
Leukocytes (1,000 /μL)	4,692±2,155	12,192±10,765	1.43 (1.19, 1.71)

Lymphocyte Percentage (%)	30.6±17.9	12.6±10.1	0.89 (0.84, 0.94)
Platelets (1,000 / μ L)	152,462±72,110	68,364±60,249	0.98 (0.97, 0.99)
SGOT (IU/L)	58.0±45.2	102.8±66.6	1.02 (1.00, 1.03)

280 ^a Displayed as mean \pm standard deviation

281 ^b Presented as odds ratio for SD (95% CI) vs. DWS-/DWS+

282

283 **Table 5.** Binomial logistic regression model of laboratory results and disease severity.

Variable	<u>SD vs. DWS-/DWS+</u>	
	OR	95% CI
Lymphocyte, %	0.92	0.86, 0.98
Platelet count, 1,000/ μ L ^a	0.987	0.975, 0.999
Chymase, mg/mL	1.17	1.03, 1.33

284 Abbreviations: CI, confidence interval; OR, odds ratio

285 ^a Three decimal places shown for clarity

286

287 **Chymase and SD**

288 Mean chymase level was significantly higher among individuals with comorbidities (11.42, st.

289 dev. 22.55) compared to those without (2.35, 9.83; $p=0.011$). Notably, the single DWS- case

290 with an elevated chymase level (Figs 1K and S1K) occurred in an individual with systemic lupus

291 erythematosus. To evaluate for a potential interaction between chymase and comorbidities on the

292 development of SD, logistic regression was performed including these two variables. Interaction

293 product terms were nonsignificant in binomial and multinomial models. Together, comorbidities

294 had an OR of 17.91 (2.75, 116.63) for binomial logistic regression (controlling for chymase);
295 chymase had an OR of 1.12 (1.05, 1.18) (controlling for comorbidities). This model had a strong
296 goodness of fit (C statistic=0.95).

297
298 Anti-NS1 antibodies may modulate chymase release by mast cells in acute dengue, and
299 interactions between chymase and cross-reactive anti-ZIKV NS1 antibodies, detected in the
300 pGOLD assay, were investigated for their association with SD. There was no association
301 between chymase level and the quantitative anti-ZIKV NS1 IgM or IgG by linear regression, and
302 no interaction was observed between anti-ZIKV NS1 IgG and chymase in binomial linear
303 regression for SD. However, anti-ZIKV NS1 IgM showed effect modification of chymase in
304 binomial linear regression such that as IgM increased, the chymase OR increased as well. With
305 no detectable anti-ZIKV NS1 IgM, the chymase OR was 1.10 (1.04, 1.17), whereas at the mean
306 level of anti-ZIKV NS1 IgM (0.02 in this population), the chymase OR was 1.21 (1.09, 1.34;
307 model fit C statistic=0.93).

308

309 **Discussion**

310 In a predominantly adult population of dengue cases in Paraguay, multiple factors were
311 associated with clinically severe dengue, including patient (age, gender, comorbidities), serologic
312 (elevated anti-DENV IgG), and laboratory variables (low platelet count, relative lymphopenia,
313 and elevated chymase).

314

315 Factors identified in the current study are generally consistent with the published dengue
316 literature. Although clinically severe dengue often occurs among children [1, 3, 24], age among

317 adults has been identified as a risk factor for poor outcomes, [17, 23, 46]. Adults are more likely
318 to develop severe bleeding, and this may be more difficult to manage than plasma leakage, for
319 which judicious fluid replacement is often effective [3, 6, 8, 17, 23, 24, 46]. Comorbid illness,
320 including poorly-controlled diabetes mellitus (hemoglobin A1c >7%) and renal disease, have
321 been associated with SD [16, 18], and hypertension has also been identified in certain studies
322 [18]. A gender difference among clinically severe dengue has varied across studies [1, 6, 13, 17,
323 18]. In our population, 66.4% of DWS-/DWS+ cases were female in comparison to only 26.1%
324 of SD cases, and this difference remained significant after controlling for age and comorbidities.
325 Although dengue is often associated with leukopenia [3, 24, 62-64], SD cases in the current
326 study had a mild leukocytosis with reduced lymphocyte percentage (and a resulting neutrophil
327 predominance). Thrombocytopenia is a common finding in SD cases and was one of the few
328 factors that demonstrated a stepwise change across disease severity categories (DWS-, DWS+,
329 and SD) [1, 3, 17, 18, 24, 38, 62].

330
331 Chymase and LBP were evaluated as two markers of clinically severe dengue based on data from
332 their use in South and Southeast Asia [31, 32, 34, 35, 38, 42-44]. Both demonstrated a crude
333 association with SD compared to DWS-/DWS+. Although LBP did not remain in the final
334 laboratory domain model, it demonstrated a stepwise increase across the categories of severity,
335 which may have limited power in this study to identify a significant difference in a binomial
336 model. Chymase, along with other mast cell degranulation factors, has been associated with
337 clinically severe dengue in several studies [32-35], and the current study confirmed this finding
338 among dengue cases in Paraguay. As clinically severe dengue appears to be more common in
339 Southeast Asia relative to the Americas [2, 65], it is important to study potential differences in

340 pathophysiology between these regions and confirm markers of severity between populations.
341 Chymase release from mast cells may be modulated by specific anti-DENV antibodies. In mice,
342 pre-treatment with anti-DENV IgG increased chymase release in an FC γ RIII-dependent manner
343 [33], and in culture, anti-NS1 IgG blocked chymase release [42]. In the current study, we
344 observed an interaction between chymase level and antibodies against the NS1 protein of ZIKV,
345 a closely related flavivirus. Further evaluation of this interaction using an array of DENV NS1
346 proteins may delineate a mechanism of protection for anti-NS1 antibodies, which demonstrate
347 epitope-specific protection or enhancement [66, 67].
348
349 Higher levels of anti-DENV IgG and undetectable anti-DENV IgM in the pGOLD multiplex
350 serologic assay were also associated with SD in our study population. These serologic results are
351 consistent with findings in secondary dengue cases, though this is difficult to determine with
352 certainty in acute-phase samples [3, 68]. Quantitative anti-DENV IgG levels in the pGOLD
353 assay correlate with DENV FRNT₅₀, and we previously observed that higher levels are
354 associated with hospitalization in dengue cases [56]. This finding was confirmed in the current
355 study when applying more consistent criteria for clinically severe dengue [3] and controlling for
356 day post-symptom onset (data not shown). However, simultaneous detection of anti-ZIKV NS1
357 IgG did not increase the risk for SD in contrast to our earlier findings [56]. Anti-DENV IgM
358 detection in the pGOLD proved more sensitive than a commercial ELISA and demonstrated little
359 cross-reactivity on the ZIKV NS1 antigen. Notably, interpretation of these results required the
360 use of a control sample that previously tested positive for anti-DENV IgM, and inclusion of a
361 calibrator with this assay would improve generalizability.
362

363 DENV serum viral load was not associated with SD in this cross-sectional study. Viral load
364 decreases rapidly over the first week post-symptom onset, and viral kinetics differ between
365 primary and secondary dengue [12, 69-77]. It is therefore difficult to capture peak viremia in
366 most clinical settings. With only a single data point for each patient in our study, the lack of
367 association between viral load and SD is not unexpected, but this highlights a potential limitation
368 of using viral load as a predictor of severity.

369
370 Difficulties in studying predictors of clinically severe dengue stem from the low proportion of
371 severe cases among all DENV infections, lack of rapid and accurate diagnostics, and variability
372 in the definition of study endpoints [3, 5, 6, 10]. The current study relied principally on DENV
373 rRT-PCR for diagnosis, with a subset of participants detected by NS1. As part of the parent study
374 design, participants typically presented with fever, which may bias this group toward more
375 severe cases [49, 78]. Nonetheless, seven factors were associated with clinically severe dengue:
376 five of these are commonly available at the acute visit (age, gender, comorbidities, platelet count,
377 and lymphocyte percentage) and chymase and anti-DENV IgG can be measured by ELISA.
378 Study designs that enroll participants based on rapid antigen test results limit the sample size
379 necessary to include enough severe cases, but this may bias the study population given the
380 clinical performance of current rapid tests [3, 25, 49, 79, 80]. However, as many pathways
381 associated with clinically severe dengue appear linked to NS1, including chymase release and
382 development of specific antibodies, improved antigen diagnostics may increase DENV detection,
383 provide prognostic information, and facilitate future studies of clinically severe dengue [12, 14,
384 29, 42, 76].

385

386 This study had several limitations. First, a single acute-phase sample was available for each
387 participant. Samples were obtained at different timepoints in relation to the development of
388 severe disease among the participants, such that the study was not designed to prospectively
389 evaluate each marker as a predictor of clinically severe dengue. Second, although all available
390 SD cases were included, the sample size was small, particularly for the detection of differences
391 among factors with relatively narrow value ranges, such as quantitative pGOLD values. Third,
392 routine labs were collected at the discretion of the care team, and as a result, not all participants
393 had laboratory values within the correct time frame. This limited the variables included in the
394 laboratory domain multivariable analysis.

395

396 Among dengue cases in Paraguay caused by DENV-1, -2, and -4, age, gender, pre-existing
397 comorbidities, elevated anti-DENV IgG, thrombocytopenia, relative lymphopenia, and elevated
398 chymase were associated with SD. These findings will aid in the early detection of potentially
399 severe dengue cases and inform the development of new prognostics for use in acute-phase and
400 serial samples from dengue cases.

401 **Acknowledgements**

402 We thank the members of the study team based at the Instituto de Investigaciones en Ciencias de
403 la Salud, Universidad Nacional de Asunción; Hospital Villa Elisa; and Hospital Central del
404 Instituto de Provisión Social, all located in Paraguay, for their dedication to this study and their
405 excellent work. We are grateful to the study participants and their families.

406 References

- 407 1. Guzman MG, Harris E. Dengue. *Lancet*. 2015;385(9966):453-65. doi: 10.1016/S0140-6736(14)60572-9.
408 PubMed PMID: 25230594.
- 409 2. L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, et al. Symptomatic Dengue in Children
410 in 10 Asian and Latin American Countries. *The New England journal of medicine*. 2016;374(12):1155-66. Epub
411 2016/03/24. doi: 10.1056/NEJMoa1503877. PubMed PMID: 27007959.
- 412 3. World Health Organization. *Dengue: guidelines for diagnosis, treatment, prevention and control*. France:
413 WHO Press; 2009.
- 414 4. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of
415 dengue: an analysis from the Global Burden of Disease Study 2013. *The Lancet Infectious diseases*. 2016;16(6):712-
416 23. doi: 10.1016/S1473-3099(16)00026-8. PubMed PMID: 26874619; PubMed Central PMCID:
417 PMCPMC5012511.
- 418 5. Rosenberger KD, Alexander N, Martinez E, Lum LCS, Dempfle CE, Junghanss T, et al. Severe dengue
419 categories as research endpoints-Results from a prospective observational study in hospitalised dengue patients.
420 *PLoS neglected tropical diseases*. 2020;14(3):e0008076. Epub 2020/03/05. doi: 10.1371/journal.pntd.0008076.
421 PubMed PMID: 32130212; PubMed Central PMCID: PMCPMC7055818 following competing interests: Dr. Wills
422 reports personal fees from Takeda Vaccines Inc, outside the submitted work, for her work as a member of the Data
423 Monitoring Committee for their dengue vaccine trials. None of the other authors had anything to disclose.
- 424 6. Sharp TM, Anderson KB, Katzelnick LC, Clapham H, Johansson MA, Morrison AC, et al. Knowledge
425 gaps in the epidemiology of severe dengue impede vaccine evaluation. *The Lancet Infectious diseases*.
426 2022;22(2):e42-e51. Epub 2021/07/16. doi: 10.1016/S1473-3099(20)30871-9. PubMed PMID: 34265259.
- 427 7. Moraes GH, de Fatima Duarte E, Duarte EC. Determinants of mortality from severe dengue in Brazil: a
428 population-based case-control study. *The American journal of tropical medicine and hygiene*. 2013;88(4):670-6. doi:
429 10.4269/ajtmh.11-0774. PubMed PMID: 23400577; PubMed Central PMCID: PMC3617850.
- 430 8. Rocha C, Silva S, Gordon A, Hammond SN, Elizondo D, Balmaseda A, et al. Improvement in hospital
431 indicators after changes in dengue case management in Nicaragua. *The American journal of tropical medicine and*
432 *hygiene*. 2009;81(2):287-92. PubMed PMID: 19635885.
- 433 9. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a
434 systematic analysis. *The Lancet Infectious diseases*. 2016. doi: 10.1016/S1473-3099(16)00146-8. PubMed PMID:
435 27091092.
- 436 10. Robinson M, Einav S. Towards Predicting Progression to Severe Dengue. *Trends Microbiol*.
437 2020;28(6):478-86. Epub 2020/01/27. doi: 10.1016/j.tim.2019.12.003. PubMed PMID: 31982232.
- 438 11. Rico-Hesse R. Dengue virus evolution and virulence models. *Clinical Infectious Diseases*. 2007;44:1462.
- 439 12. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. Kinetics of viremia and NS1 antigenemia are shaped
440 by immune status and virus serotype in adults with dengue. *PLoS neglected tropical diseases*. 2011;5(9):e1309.
- 441 13. Guilarde AO, Turchi MD, Siqueira JB, Jr., Feres VC, Rocha B, Levi JE, et al. Dengue and dengue
442 hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response. *The Journal*
443 *of infectious diseases*. 2008;197(6):817-24. Epub 2008/02/14. doi: 10.1086/528805. PubMed PMID: 18269315.
- 444 14. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High circulating levels of
445 the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue

- 446 hemorrhagic fever. *The Journal of infectious diseases*. 2002;186(8):1165-8. doi: 10.1086/343813. PubMed PMID:
447 12355369.
- 448 15. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic
449 fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.
450 *Archives of virology*. 2013;158(7):1445-59. Epub 2013/03/09. doi: 10.1007/s00705-013-1645-3. PubMed PMID:
451 23471635.
- 452 16. Lee IK, Hsieh CJ, Lee CT, Liu JW. Diabetic patients suffering dengue are at risk for development of
453 dengue shock syndrome/severe dengue: Emphasizing the impacts of co-existing comorbidity(ies) and glycemic
454 control on dengue severity. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*.
455 2020;53(1):69-78. Epub 2018/08/28. doi: 10.1016/j.jmii.2017.12.005. PubMed PMID: 30146413.
- 456 17. Pinto RC, Castro DB, Albuquerque BC, Sampaio Vde S, Passos RA, Costa CF, et al. Mortality Predictors
457 in Patients with Severe Dengue in the State of Amazonas, Brazil. *PloS one*. 2016;11(8):e0161884. Epub 2016/08/27.
458 doi: 10.1371/journal.pone.0161884. PubMed PMID: 27564084; PubMed Central PMCID: PMCPMC5001629.
- 459 18. Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Furuya-Kanamori L, Wangdi K. Clinical predictors of
460 severe dengue: a systematic review and meta-analysis. *Infect Dis Poverty*. 2021;10(1):123. Epub 2021/10/11. doi:
461 10.1186/s40249-021-00908-2. PubMed PMID: 34627388; PubMed Central PMCID: PMCPMC8501593.
- 462 19. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent
463 enhancement of severe dengue disease in humans. *Science*. 2017;358(6365):929-32. Epub 2017/11/04. doi:
464 10.1126/science.aan6836. PubMed PMID: 29097492; PubMed Central PMCID: PMCPMC5858873.
- 465 20. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue
466 virus correlate with protection from symptomatic infection in a longitudinal cohort. *Proceedings of the National
467 Academy of Sciences of the United States of America*. 2016;113(3):728-33. doi: 10.1073/pnas.1522136113.
468 PubMed PMID: 26729879.
- 469 21. Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, et al.
470 Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. *Nature*. 2018;557(7707):719-
471 23. Epub 2018/05/26. doi: 10.1038/s41586-018-0157-4. PubMed PMID: 29795354; PubMed Central PMCID:
472 PMCPMC6064976.
- 473 22. Waggoner JJ, Katzelnick LC, Burger-Calderon R, Gallini J, Moore RH, Kuan G, et al. Antibody-
474 Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections.
475 *The Journal of infectious diseases*. 2020;221(11):1846-54. Epub 2020/04/03. doi: 10.1093/infdis/jiz618. PubMed
476 PMID: 32236481; PubMed Central PMCID: PMCPMC7213574.
- 477 23. Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges.
478 *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*.
479 2003;27(1):1-13. Epub 2003/05/03. doi: 10.1016/s1386-6532(03)00010-6. PubMed PMID: 12727523.
- 480 24. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC, et al. Differences in dengue
481 severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. *The American journal of
482 tropical medicine and hygiene*. 2005;73(6):1063-70. Epub 2005/12/16. PubMed PMID: 16354813.
- 483 25. Robinson M, Sweeney TE, Barouch-Bentov R, Sahoo MK, Kalesinskas L, Vallania F, et al. A 20-Gene Set
484 Predictive of Progression to Severe Dengue. *Cell Rep*. 2019;26(5):1104-11 e4. Epub 2019/01/31. doi:
485 10.1016/j.celrep.2019.01.033. PubMed PMID: 30699342; PubMed Central PMCID: PMCPMC6352713.
- 486 26. Assuncao-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, Souza DG, et al. Contribution of
487 macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. *FASEB J*. 2010;24(1):218-28.
488 Epub 2009/09/25. doi: 10.1096/fj.09-139469. PubMed PMID: 19776337.

- 489 27. Jeewandara C, Gomes L, Udari S, Paranavitane SA, Shyamali NL, Ogg GS, et al. Secretory phospholipase
490 A2 in the pathogenesis of acute dengue infection. *Immun Inflamm Dis*. 2017;5(1):7-15. Epub 2017/03/03. doi:
491 10.1002/iid3.135. PubMed PMID: 28250920; PubMed Central PMCID: PMC5322161.
- 492 28. Jeewandara C, Gomes L, Wickramasinghe N, Gutowska-Owsiak D, Waithe D, Paranavitane SA, et al.
493 Platelet activating factor contributes to vascular leak in acute dengue infection. *PLoS neglected tropical diseases*.
494 2015;9(2):e0003459. Epub 2015/02/04. doi: 10.1371/journal.pntd.0003459. PubMed PMID: 25646838; PubMed
495 Central PMCID: PMC4315531.
- 496 29. Chen HR, Chao CH, Liu CC, Ho TS, Tsai HP, Perng GC, et al. Macrophage migration inhibitory factor is
497 critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability. *PLoS pathogens*.
498 2018;14(4):e1007033. Epub 2018/04/28. doi: 10.1371/journal.ppat.1007033. PubMed PMID: 29702687; PubMed
499 Central PMCID: PMC6044858.
- 500 30. Chen HR, Chuang YC, Lin YS, Liu HS, Liu CC, Perng GC, et al. Dengue Virus Nonstructural Protein 1
501 Induces Vascular Leakage through Macrophage Migration Inhibitory Factor and Autophagy. *PLoS neglected*
502 *tropical diseases*. 2016;10(7):e0004828. Epub 2016/07/15. doi: 10.1371/journal.pntd.0004828. PubMed PMID:
503 27409803; PubMed Central PMCID: PMC4943727.
- 504 31. Furuta T, Murao LA, Lan NT, Huy NT, Huong VT, Thuy TT, et al. Association of mast cell-derived VEGF
505 and proteases in Dengue shock syndrome. *PLoS neglected tropical diseases*. 2012;6(2):e1505. Epub 2012/03/01.
506 doi: 10.1371/journal.pntd.0001505. PubMed PMID: 22363824; PubMed Central PMCID: PMC3283553.
- 507 32. St John AL, Rathore AP, Raghavan B, Ng ML, Abraham SN. Contributions of mast cells and vasoactive
508 products, leukotrienes and chymase, to dengue virus-induced vascular leakage. *Elife*. 2013;2:e00481. Epub
509 2013/05/03. doi: 10.7554/eLife.00481. PubMed PMID: 23638300; PubMed Central PMCID: PMC3639510.
- 510 33. Syenina A, Jagaraj CJ, Aman SA, Sridharan A, St John AL. Dengue vascular leakage is augmented by mast
511 cell degranulation mediated by immunoglobulin Fcγ receptors. *Elife*. 2015;4. Epub 2015/03/19. doi:
512 10.7554/eLife.05291. PubMed PMID: 25783751; PubMed Central PMCID: PMC4362203.
- 513 34. Tissera H, Rathore APS, Leong WY, Pike BL, Warkentien TE, Farouk FS, et al. Chymase Level Is a
514 Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients. *The Journal of infectious*
515 *diseases*. 2017;216(9):1112-21. Epub 2017/10/03. doi: 10.1093/infdis/jix447. PubMed PMID: 28968807; PubMed
516 Central PMCID: PMC5853622.
- 517 35. Rathore APS, Senanayake M, Athapathu AS, Gunasena S, Karunaratna I, Leong WY, et al. Serum chymase
518 levels correlate with severe dengue warning signs and clinical fluid accumulation in hospitalized pediatric patients.
519 *Scientific reports*. 2020;10(1):11856. Epub 2020/07/18. doi: 10.1038/s41598-020-68844-z. PubMed PMID:
520 32678248; PubMed Central PMCID: PMC7367272.
- 521 36. King CA, Wegman AD, Endy TP. Mobilization and Activation of the Innate Immune Response to Dengue
522 Virus. *Front Cell Infect Microbiol*. 2020;10:574417. Epub 2020/11/24. doi: 10.3389/fcimb.2020.574417. PubMed
523 PMID: 33224897; PubMed Central PMCID: PMC7670994.
- 524 37. Sherif NA, Zayan AH, Elkady AH, Ghozy S, Ahmed AR, Omran ES, et al. Mast cell mediators in relation
525 to dengue severity: A systematic review and meta-analysis. *Rev Med Virol*. 2020;30(1):e2084. Epub 2019/11/12.
526 doi: 10.1002/rmv.2084. PubMed PMID: 31709696.
- 527 38. Sahu AK, Aggarwal P, Ekka M, Nayer J, Bhoi S, Kumar A, et al. Assessing the serum chymase level as an
528 early predictor of dengue severity. *Journal of medical virology*. 2021;93(6):3330-7. Epub 2020/08/29. doi:
529 10.1002/jmv.26468. PubMed PMID: 32857465.
- 530 39. Seet RC, Chow AW, Quek AM, Chan YH, Lim EC. Relationship between circulating vascular endothelial
531 growth factor and its soluble receptors in adults with dengue virus infection: a case-control study. *International*

- 532 journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
533 2009;13(5):e248-53. Epub 2009/03/06. doi: 10.1016/j.ijid.2008.11.028. PubMed PMID: 19261502.
- 534 40. Srikiatkachorn A, Ajariyakhajorn C, Endy TP, Kalayanarooj S, Libraty DH, Green S, et al. Virus-induced
535 decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic
536 Fever. *Journal of virology*. 2007;81(4):1592-600. Epub 2006/12/08. doi: 10.1128/JVI.01642-06. PubMed PMID:
537 17151115; PubMed Central PMCID: PMCPCMC1797579.
- 538 41. Patra G, Saha B, Mukhopadhyay S. Study of serum VEGF levels in patients with severe dengue infection
539 admitted in a tertiary care hospital in Kolkata. *Journal of medical virology*. 2019;91(10):1873-6. Epub 2019/06/28.
540 doi: 10.1002/jmv.25529. PubMed PMID: 31243775.
- 541 42. Chu YT, Wan SW, Chang YC, Lee CK, Wu-Hsieh BA, Anderson R, et al. Antibodies against nonstructural
542 protein 1 protect mice from dengue virus-induced mast cell activation. *Lab Invest*. 2017. Epub 2017/02/28. doi:
543 10.1038/labinvest.2017.10. PubMed PMID: 28240747.
- 544 43. van de Weg CA, Koraka P, van Gorp EC, Mairuhu AT, Supriatna M, Soemantri A, et al.
545 Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. *Journal*
546 *of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2012;53(1):38-42.
547 Epub 2011/10/22. doi: 10.1016/j.jcv.2011.09.028. PubMed PMID: 22014848.
- 548 44. van de Weg CA, Pannuti CS, de Araujo ES, van den Ham HJ, Andeweg AC, Boas LS, et al. Microbial
549 translocation is associated with extensive immune activation in dengue virus infected patients with severe disease.
550 *PLoS neglected tropical diseases*. 2013;7(5):e2236. Epub 2013/05/30. doi: 10.1371/journal.pntd.0002236. PubMed
551 PMID: 23717702; PubMed Central PMCID: PMCPCMC3662706.
- 552 45. Kamaladasa A, Gomes L, Jeewandara C, Shyamali NL, Ogg GS, Malavige GN. Lipopolysaccharide acts
553 synergistically with the dengue virus to induce monocyte production of platelet activating factor and other
554 inflammatory mediators. *Antiviral research*. 2016;133:183-90. Epub 2016/08/01. doi:
555 10.1016/j.antiviral.2016.07.016. PubMed PMID: 27476044.
- 556 46. Lee IK, Liu JW, Yang KD. Clinical and laboratory characteristics and risk factors for fatality in elderly
557 patients with dengue hemorrhagic fever. *The American journal of tropical medicine and hygiene*. 2008;79(2):149-
558 53. Epub 2008/08/12. PubMed PMID: 18689614.
- 559 47. Jayaratne SD, Atukorale V, Gomes L, Chang T, Wijesinghe T, Fernando S, et al. Evaluation of the WHO
560 revised criteria for classification of clinical disease severity in acute adult dengue infection. *BMC research notes*.
561 2012;5:645. Epub 2012/11/22. doi: 10.1186/1756-0500-5-645. PubMed PMID: 23167997; PubMed Central PMCID:
562 PMCPCMC3534490.
- 563 48. Suresh SC, Hanumanthaiah R, Ramakrishna C, Sandeep R, Narasimhasetty PS, Ramakrishna V, et al.
564 Serum Ferritin As a Prognostic Indicator in Adult Dengue Patients. *The American journal of tropical medicine and*
565 *hygiene*. 2020;104(3):1072-8. Epub 2020/12/30. doi: 10.4269/ajtmh.20-1111. PubMed PMID: 33372649; PubMed
566 Central PMCID: PMCPCMC7941811.
- 567 49. Rojas A, Cardozo F, Cantero C, Stittleburg V, Lopez S, Bernal C, et al. Characterization of dengue cases
568 among patients with an acute illness, Central Department, Paraguay. *PeerJ*. 2019;7:e7852. Epub 2019/10/17. doi:
569 10.7717/peerj.7852. PubMed PMID: 31616598; PubMed Central PMCID: PMCPCMC6790102.
- 570 50. Pan American Health Organization. Dengue 2021 [01 July 2022]. Available from:
571 <https://www3.paho.org/data/index.php/es/temas/indicadores-dengue.html>.
- 572 51. Lovera D, Martinez-Cuellar C, Galeano F, Amarilla S, Vazquez C, Arbo A. Clinical manifestations of
573 primary and secondary dengue in Paraguay and its relation to virus serotype. *Journal of infection in developing*
574 *countries*. 2019;13(12):1127-34. Epub 2020/02/24. doi: 10.3855/jidc.11584. PubMed PMID: 32088700.

- 575 52. Vázquez C, Villalba S, Gamarra ML, Oviedo E, Oviedo A, Ortega MJ, et al. Características Viroológicas y
576 Serológicas de Pacientes con Dengue Grave y Fallecidos por Dengue durante la Epidemia del Año 2011 en
577 Paraguay. *Rev Inst Med Trop.* 2012;7:8-18.
- 578 53. Martínez de Cuellar C, Lovera D, Arbo A. Factores de riesgo asociados a mortalidad por Dengue en
579 menores de 15 años. Paraguay, periodo 2010-2013. *Pediatr (Asunción).* 2017;44(2):136-42.
- 580 54. Rios González CM. La investigación científica en Dengue, Zika y Chikungunya: evaluación bibliométrica
581 de las contribuciones de la literatura paraguaya. *Rev Cient Cienc Med.* 2016;19:65.
- 582 55. Talarico LB, Byrne AB, Amarilla S, Lovera D, Vazquez C, Chamorro G, et al. Characterization of type I
583 interferon responses in dengue and severe dengue in children in Paraguay. *Journal of clinical virology : the official
584 publication of the Pan American Society for Clinical Virology.* 2017;97:10-7. Epub 2017/10/28. doi:
585 10.1016/j.jcv.2017.10.010. PubMed PMID: 29078078.
- 586 56. Rojas A, Natrajan MS, Weber J, Cardozo F, Cantero C, Ananta JS, et al. Comparison of Anti-Dengue and
587 Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing. *The American journal of tropical
588 medicine and hygiene.* 2021. Epub 2021/03/31. doi: 10.4269/ajtmh.20-1449. PubMed PMID: 33782214; PubMed
589 Central PMCID: PMCPCMC8103464.
- 590 57. Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Davila MJ, Tellez Y, et al. Single-Reaction
591 Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. *Emerging
592 infectious diseases.* 2016;22(7):1295-7. doi: 10.3201/eid2207.160326. PubMed PMID: 27184629; PubMed Central
593 PMCID: PMC4918162.
- 594 58. Waggoner JJ, Abeynayake J, Sahoo MK, Gresh L, Tellez Y, Gonzalez K, et al. Comparison of the FDA-
595 approved CDC DENV-1-4 real-time reverse transcription-PCR with a laboratory-developed assay for dengue virus
596 detection and serotyping. *Journal of clinical microbiology.* 2013;51(10):3418-20. doi: 10.1128/JCM.01359-13.
597 PubMed PMID: 23903549; PubMed Central PMCID: PMC3811623.
- 598 59. Waggoner JJ, Abeynayake J, Sahoo MK, Gresh L, Tellez Y, Gonzalez K, et al. Single-reaction, multiplex,
599 real-time rt-PCR for the detection, quantitation, and serotyping of dengue viruses. *PLoS neglected tropical diseases.*
600 2013;7(4):e21116. doi: 10.1371/journal.pntd.0002116. PubMed PMID: 23638191; PubMed Central PMCID:
601 PMC3630127.
- 602 60. Zhang B, Pinsky BA, Ananta JS, Zhao S, Arulkumar S, Wan H, et al. Diagnosis of Zika virus infection on a
603 nanotechnology platform. *Nature medicine.* 2017;23(5):548-50. Epub 2017/03/07. doi: 10.1038/nm.4302. PubMed
604 PMID: 28263312.
- 605 61. Dirección General de Vigilancia de la Salud, Ministerio de Salud Pública y Bienestar Social. Boletín
606 Epidemiológico: Semana Epidemiológica 52. 2021;(52).
- 607 62. Lee VJ, Chow A, Zheng X, Carrasco LR, Cook AR, Lye DC, et al. Simple clinical and laboratory
608 predictors of Chikungunya versus dengue infections in adults. *PLoS neglected tropical diseases.* 2012;6(9):e1786.
609 doi: 10.1371/journal.pntd.0001786. PubMed PMID: 23029573; PubMed Central PMCID: PMC3459852.
- 610 63. Chadwick D, Arch B, Wilder-Smith A, Paton N. Distinguishing dengue fever from other infections on the
611 basis of simple clinical and laboratory features: application of logistic regression analysis. *Journal of clinical
612 virology : the official publication of the Pan American Society for Clinical Virology.* 2006;35(2):147-53. Epub
613 2005/08/02. doi: 10.1016/j.jcv.2005.06.002. PubMed PMID: 16055371.
- 614 64. Potts JA, Rothman AL. Clinical and laboratory features that distinguish dengue from other febrile illnesses
615 in endemic populations. *Tropical medicine & international health : TM & IH.* 2008;13(11):1328-40. doi:
616 10.1111/j.1365-3156.2008.02151.x. PubMed PMID: 18803612; PubMed Central PMCID: PMC2756447.

- 617 65. Halstead SB. Dengue in the Americas and Southeast Asia: do they differ? *Revista panamericana de salud publica = Pan American journal of public health*. 2006;20(6):407-15. PubMed PMID: 17341332.
618
- 619 66. Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. The Good, the Bad, and the Shocking: The Multiple
620 Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis. *Annu Rev Virol*. 2018;5(1):227-53.
621 Epub 2018/07/26. doi: 10.1146/annurev-virology-101416-041848. PubMed PMID: 30044715; PubMed Central
622 PMCID: PMC6311996.
- 623 67. Jayathilaka D, Gomes L, Jeewandara C, Jayarathna GSB, Herath D, Perera PA, et al. Role of NS1
624 antibodies in the pathogenesis of acute secondary dengue infection. *Nat Commun*. 2018;9(1):5242. Epub
625 2018/12/12. doi: 10.1038/s41467-018-07667-z. PubMed PMID: 30531923; PubMed Central PMCID:
626 PMC6286345.
- 627 68. Nguyen THT, Clapham HE, Phung KL, Nguyen TK, TT DI, Nguyen THQ, et al. Methods to discriminate
628 primary from secondary dengue during acute symptomatic infection. *BMC infectious diseases*. 2018;18(1):375.
629 Epub 2018/08/09. doi: 10.1186/s12879-018-3274-7. PubMed PMID: 30086716; PubMed Central PMCID:
630 PMC6081805.
- 631 69. Duyen HT, Ngoc TV, Ha do T, Hang VT, Kieu NT, Young PR, et al. Kinetics of plasma viremia and
632 soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune
633 status. *The Journal of infectious diseases*. 2011;203(9):1292-300. doi: 10.1093/infdis/jir014. PubMed PMID:
634 21335562; PubMed Central PMCID: PMC63069728.
- 635 70. Libraty DH, Endy TP, Hough HS, Green S, Kalayanaraj S, Suntayakorn S, et al. Differing influences of
636 virus burden and immune activation on disease severity in secondary dengue-3 virus infections. *The Journal of*
637 *infectious diseases*. 2002;185(9):1213-21. Epub 2002/05/10. doi: 10.1086/340365. PubMed PMID: 12001037.
- 638 71. Nunes PC, Sampaio SA, da Costa NR, de Mendonca MC, Lima Mda R, Araujo SE, et al. Dengue severity
639 associated with age and a new lineage of dengue virus-type 2 during an outbreak in Rio De Janeiro, Brazil. *Journal*
640 *of medical virology*. 2016;88(7):1130-6. Epub 2016/04/12. doi: 10.1002/jmv.24464. PubMed PMID: 27061403.
- 641 72. Vaughn DW, Green S, Kalayanaraj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia
642 titer, antibody response pattern, and virus serotype correlate with disease severity. *The Journal of infectious*
643 *diseases*. 2000;181:2.
- 644 73. Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, et al. High levels of plasma dengue viral load
645 during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. *Virology*.
646 2003;305(2):330-8. Epub 2003/02/08. PubMed PMID: 12573578.
- 647 74. Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, et al. Slower rates of clearance of viral
648 load and virus-containing immune complexes in patients with dengue hemorrhagic fever. *Clinical infectious*
649 *diseases : an official publication of the Infectious Diseases Society of America*. 2006;43(8):1023-30. Epub
650 2006/09/20. doi: 10.1086/507635. PubMed PMID: 16983615.
- 651 75. Nguyen MT, Ho TN, Nguyen VV, Nguyen TH, Ha MT, Ta VT, et al. An Evidence-Based Algorithm for
652 Early Prognosis of Severe Dengue in the Outpatient Setting. *Clinical infectious diseases : an official publication of*
653 *the Infectious Diseases Society of America*. 2017;64(5):656-63. Epub 2016/12/31. doi: 10.1093/cid/ciw863.
654 PubMed PMID: 28034883; PubMed Central PMCID: PMC635850639.
- 655 76. Nunes PCG, Nogueira RMR, Heringer M, Chouin-Carneiro T, Damasceno Dos Santos Rodrigues C, de
656 Filippis AMB, et al. NS1 Antigenemia and Viraemia Load: Potential Markers of Progression to Dengue Fatal
657 Outcome? *Viruses*. 2018;10(6). Epub 2018/06/16. doi: 10.3390/v10060326. PubMed PMID: 29903980; PubMed
658 Central PMCID: PMC6024368.

- 659 77. Thomas L, Verlaeten O, Cabie A, Kaidomar S, Moravie V, Martial J, et al. Influence of the dengue
660 serotype, previous dengue infection, and plasma viral load on clinical presentation and outcome during a dengue-2
661 and dengue-4 co-epidemic. *The American journal of tropical medicine and hygiene*. 2008;78(6):990-8. PubMed
662 PMID: 18541782.
- 663 78. Tukasan C, Furlan NB, Estofolete CF, Nogueira ML, da Silva NS. Evaluation of the importance of fever
664 with respect to dengue prognosis according to the 2009 WHO classification: a retrospective study. *BMC infectious
665 diseases*. 2017;17(1):6. Epub 2017/01/06. doi: 10.1186/s12879-016-2128-4. PubMed PMID: 28052760; PubMed
666 Central PMCID: PMC5209937.
- 667 79. Liu YE, Saul S, Rao AM, Robinson ML, Agudelo Rojas OL, Sanz AM, et al. An 8-gene machine learning
668 model improves clinical prediction of severe dengue progression. *Genome Med*. 2022;14(1):33. Epub 2022/03/30.
669 doi: 10.1186/s13073-022-01034-w. PubMed PMID: 35346346; PubMed Central PMCID: PMC8959795.
- 670 80. Guzman MG, Jaenisch T, Gaczkowski R, Hang VTT, Sekaran SD, Kroeger A, et al. Multi-country
671 evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis.
672 *PLoS neglected tropical diseases*. 2010;4(8):e811.
673